Guideline on the management of Psoriasis in South Africa

South African Medical Journal

Volumn 100, Issue 4, 2010, Pages 257-282

  Raboobee, N ^a   Aboobaker, J ^a   Jordaan, H F ^a   Sinclair, W ^a   Smith, J M ^a   Todd, G ^a   Weiss, R ^a   Whitaker, D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; CYTOKINE; DERMATOLOGICAL AGENT; GLUCOCORTICOID; IMMUNOLOGIC FACTOR;

ARTICLE; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; HEALTH CARE PERSONNEL; HEREDITY; HUMAN; MEDICAL SOCIETY; MENTAL STRESS; MORBIDITY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PSORIASIS; QUALITY OF LIFE; SOUTH AFRICA; DIFFERENTIAL DIAGNOSIS; LOW LEVEL LASER THERAPY; PATIENT REFERRAL; PHOTOTHERAPY; SEVERITY OF ILLNESS INDEX;

DERMATOLOGIC AGENTS; DIAGNOSIS, DIFFERENTIAL; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; LASER THERAPY; PHOTOTHERAPY; PSORIASIS; REFERRAL AND CONSULTATION; SEVERITY OF ILLNESS INDEX; SOUTH AFRICA;

EID: 77950386579     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (95)

1. Ashcroft DM, Li Wan Po A, Griffiths CE. Therapeutic strategies for psoriasis. J Clin Pharm Ther 2000; 25: 1-10.
2. Choi J, Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol 2003; 49: S57-S61.
3. Brandrup F, Green A. The prevalence of psoriasis in Denmark. Acta Derm Venereol 1981; 61: 344-346.
4. Henseler T, Christophers E. Psoriasis of early and late onset: Characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985; 13: 450-456.
5. Elder JT, Nair RP, Guo SW, Henseler T, Christophers E, Voorhees JJ. The genetics of psoriasis. Arch Dermatol 1994; 130(2): 216-224.
6. Whittam LR, McGibbon DH. The management of psoriasis. Int J Clin Pract 1998; 52: 487-491.
7. Asumalahti K, et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J Invest Dermatol 2003; 120(4): 627-632.
8. Swanbeck G, et al. Genetic counseling in psoriasis. Empirical data on psoriasis among first-degree relatives of 3095 psoriatic probands. Br J Dermatol 1997; 137(6): 939-942.
9. Lebwohl M. Psoriasis. Lancet 2003; 361(9364): 1197-1204.
10. Travis L, Weinberg JM. Medical backgrounder: Psoriasis. Drugs Today (Barc) 2002; 38: 847-865.
11. Christophers E. Psoriasis - epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314-320.
12. Nijsten T, Meads DM, De Korte J, et al. Cross-cultural inequivalence of dermatology-specific health-related quality of life instruments in psoriasis patients. J Invest Dermatol 2007; 127: 2315-2322.
13. Menter A, Gottlieb A, Feldman SR, et al. Guidelines for the care and management of psoriasis and psoriatic arthritis. J Am Acad Dermatol 2008; 58: 826-850.
14. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19(3): 210-216.
15. Krueger GG, Feldman SR, Camisa C, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000; 43: 281-285.
16. Feldman SR. A quantitative definition of severe psoriasis for use in clinical trials. J Dermatolog Treat 2004; 15: 27-29.
17. Lebwohl M, Menter A, Koo J, et al. In: Portland OR, ed. Psoriasis: Treatment Options and Patient Management. Physician Patient Guide. National Psoriasis Foundation, 2002: 30-31. http://www.psoriasis.org/files/pdfs/press/algorithm.pdf (accessed 12 February 2009).
18. Brandrup F, Green A. The prevalence of psoriasis in Denmark. Acta Derm Venereol 1981; 61: 344-346.
19. Lebwohl M, Christophers E, Langley R, et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003; 139: 719-727.
20. Linden KG, Weinstein GD. Psoriasis: current perspectives with an emphasis on treatment. Am J Med 1999; 107: 595-605.
21. Koo J, Lebwohl M. Duration of remission of psoriasis therapies. J Am Acad Dermatol 1999; 41: 51-59.
22. Lebwohl M, Ali S. Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol 2001; 45: 649-661.
23. Compendium of pharmaceuticals and specialties. Ed. Ottawa: Canadian Pharmacists Association, 2004.
24. Boerbooms AM, Kerstens PJ, van Loenhout JW, et al. Infections during low-dose methotrexate treatment in rheumatoid arthritis. Semin Arthritis Rheum 1995; 24: 411-421.
25. Lebwohl M, Menter A, Koo J, et al. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol 2004; 50: 416-430.
26. Weinstein GD, White GM. An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol 1993; 28: 454-459.
27. Koo J. Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results. J Am Acad Dermatol 1999; 41: S25-S28.
28. van de Kerkhof PC. The management of psoriasis. Neth J Med 1998; 52: 40-45.
29. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280-284.
30. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-407.
31. Naldi L, Svensson A, Diepgen T, et al. Randomized clinical trials for psoriasis 1977-2000: the EDEN survey. J Invest Dermatol 2003; 120: 738-741.
32. Nast A, Kopp IB, Augustin M, Banditt KB, et al. Deutsche Dermatologische Gesellschaft (DDG); Berufsverband Deutscher Dermatologen (BVDD).Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. J Dtsch Dermatol Ges 2007; 5 (Suppl 3): 1-119.
33. Nast A, Kopp I, Augustin M, et al. German evidence-based guidelines for the treatment of psoriasis vulgaris (short version). Arch Dermatol Res 2007; 299(3): 111-138.
34. Lebwohl M, Freeman AK, Chapman MS, et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 2004; 51(5): 723-730.
35. Mentor A, Griffiths CEM. Psoriasis 2. Current and future management of psoriasis. Lancet 2007; 370: 272-284.
36. Griffiths CEM, Clark CM, Chalmers RJ, et al. A systematic review of treatments for severe psoriasis. Health Technol Assess 2000; 4: 1-125.
37. Chalmers RJG. Psoriasis. In: Williams HC, ed. Evidence-based Dermatology. 1st ed. London: Blackwell Publishing, 2003: 226-252.
38. Naldi L, Griffiths CEM. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 2005; 152: 597-615.
39. Yamauchi PS, Rizk D, Lowe NJ. Retinoid therapy for psoriasis. Dermatol Clin 2004; 22: 467-476.
40. Marsland AM, Chalmers RJ, Hollis S, et al. Interventions for chronic palmoplantar pustulosis (Review). Cochrane Database Syst Rev 2006, Issue 1. Art. No.: CD001433. DOI:10.1002/14651858.CD001433.
41. Jones G, Crotty M, Brooks P. Interventions for treating psoriatic arthritis (Review). Cochrane Database Syst Rev 2000, Issue 3. Art. No.: CD000212. DOI: 10.1002/14651858.CD000212.
42. Tey HL, Tian EL, Tan AW. Drug interactions in dermatological practice. Clin Expt Dermatol 2008; 33: 541-550.
43. Naldi L, Chalmers RJG. Psoriasis. In: Williams HC, ed. Evidence-based Dermatology. 2nd ed. London: Blackwell Publishing, 2008: 171-188.
44. Sandhu K, Kaur I, Kumar B, et al. Efficacy and safety of cyclosporine versus methotrexate in severe psoriasis: a study from north India. J Dermatol 2003; 30: 458-463.
45. Heydendael VMR, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003; 349: 658-665.
46. Flyström I, Stenberg B, Svensson Å et al. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2008; 158: 116-121.
47. Schmitt J, Zhang Z, Wozel G, et al. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2008; 159: 513-526.
48. Griffiths CEM, Dubertret L, Ellis CN, et al. Ciclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol 2004; 150 (Suppl 67): 11-23.
49. Saurat J-H, Stingl G, Dubertret L, et al. for the CHAMPION Study Investigators. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methrotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-566.
50. Ortiz Z, Shea B, Suarez Almazor M, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 1999, Issue 3. Art. No.: CD000951. DOI: 10.1002/14651858.CD000951.
51. van Ede AE, Laan RFJM, Rood MJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week multicentre, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001; 44: 1515-1524.
52. Salim A, Tan E, Ilchyshyn A, et al. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial. Br J Dermatol 2006; 154: 1169-1174.
53. Chládek J, Simková M, Vanecková J, et al. The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis. Eur J Clin Pharmacol 2008; 64: 347-355.
54. British Association of Dermatologists Guidelines. Psoriasis-general management. http://www.bad.org.uk/site/769/default.aspx (accessed 18 March 2009).
55. Smith CH. Use of hydroxyurea in psoriasis. Clin Exp Dermatol 1999; 24: 2-6.
56. Lori F, Lisziewicz J. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug. Clin Infect Dis 2000; 30 (Suppl 2): S193-S197.
57. Kumar B, Saraswat A, Kaur I. Rediscovering hydroxyurea: its role in recalcitrant psoriasis. Int J Dermatol 2001; 40: 530-534.
58. Lewis V, Finlay AY. Ten years experience of the Dermatology Life Quality Index (DLQI). J Invest Dermatol Symp Proc 2004; 9: 169-180.
59. Ashcroft DM, Li Wan, et al. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 1999; 141: 185-191.
60. Finlay AY. Current severe psoriasis and the Rule of Tens. Br J Dermatol 2005; 152: 861-867.
61. Ibbotson SH, Bilsland D, Cox NH, et al. An update and guidance on narrowband ultraviolet B phototherapy: a British Photodermatology Group Workshop Report. Br J Dermatol 2004; 151: 283-297.
62. Smith CH, Anstey AV, Barker JNWN, et al and Ormerod AD (Chair of the Guideline Group). British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005; 153: 486-497.
63. Thaçi D. Long-term data in the treatment of psoriasis. Br J Dermatol 2008; 159 (Suppl. 2): 18-24.
64. Alefacept package insert. http://www.astellas.us/docs/amevive.pdf (accessed 26 March 2009).
65. Hodak E, David M. Alefacept: a review of the literature and practical guidelines for management. Dermatol Ther 2004; 17: 383-392.
66. Cooper KD, Korman NJ. Alefacept in the treatment of psoriasis. Clin Dermatol 2008; 26: 503-508.
67. European Medicines Agency recommends suspension of the marketing authorisation of Raptiva (efalizumab). www.emea.europa.eu/humandocs/PDFs/EPAR/raptiva/2085709en.pdf (accessed 26 March 2009).
68. Adalimumab Package Insert. http://www.rxabbott.com/pdf/humira.pdf (accessed 26 March 2009).
69. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomised, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-115.
70. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55: 598-606.
71. Etanercept Package Insert. //www.enbrel.com/pdf/enbrel_pi.pdf http://www.enbrel.com/pdf/enbrel_pi.pdf (accessed 26 March 2009).
72. Goffe B, Cather JC. Etanercept: An overview. J Am Acad Dermatol 2003; 49 (2 Suppl): S105-S111.
73. Gottlieb AB, Matheson, RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627-1632.
74. Paller AS, Sigfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008; 358: 241-251.
75. Mease PJ, Kivitz, AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004, 50: 2264-2272.
76. Lebwohl MG, Gottlieb AB, Walis WJ, Zitnik RJ. Global safety and efficacy of more than five years of etanercept (Enbrel) therapy in rheumatoid arthritis. American Academy of Dermatology 62nd Annual Meeting 2004: Washington, DC, poster P550. J Am Acad Dermatol 2004 (Suppl 3); 50: 142.
77. Infliximab Package Insert. http://www.remicade.com/remicade/assets/HCP_PPI.pdf (accessed 26 March 2009).
78. Reich K, Nestle FO, Papp K, et al for the EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-1374.
79. Data on file. Schering-Plough Pharmaceuticals. http://www.centocororthobiotech.com/cobi/viewDocumentByTitleAlias.html?title=PR_REMICADE_SONIC_JUNE0209 (accessed 30 June 2009).
80. Winterfield LS. Infliximab. Dermatol Ther 2004; 17: 409-426.
81. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003; 138: 807-811.
82. Sarzi-Puttini P, Ardizzone S, Manzionna G, et al. Infliximab-induced lupus in Crohn's disease: a case report. Dig Liver Dis 2003; 35: 814-817.
83. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-608.
84. Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanism could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 2001; 44: 1977-1983.
85. Ustekinumab EU. Summary of product characteristics. http://www.stelarainfo.com/assets/pdf/PrescribingInformation.pdf (accessed 15 January 2010).
86. Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression on interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004; 199: 125-130.
87. Kimball AB, Gordon KB, Langley RG, Menter A, Chartash EK, Valdes J for the ABT-874 Psoriasis Study Investigators. Safety and efficacy of abt-874, a fully human interleukin 12/23monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis. Results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 2008; 144(2): 200-207.
88. Leonardi CL, Kimball AB, Papp KA, et al. for the PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-1674.
89. Papp KA, Langley RG, Lebwohl M, et al for the PHOENIX 2 Study Investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-1684.
90. Gottlieb A, Menter A, Mendelsohn A, Shen Y-K, Li S, Guzzo C, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373: 633-640.
91. Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A. Safety and efficacy of alefacept, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized, controlled trials. Br J Dermatol 2008; 159: 274-285.
92. Griffiths CEM, Strober B, van der Kerkhof PCM, et al. Comparing ustekinumab and etanercept for the treatment of moderate to severe plaque psoriasis. Poster FP1336, presented at EADV (European Academy of Dermatology and Venereology), 17-21 September 2008, Paris.
93. Hawkins N, Huntley A, Eaton J. Meta-analysis of biologic therapies for the treatment of moderate to severe psoriasis. Poster presented at ISPOR (International Society for Pharmacoeconomics and Outcomes Research), 18 May 2009, Orlando, USA.
94. Winhoven SM, Griffiths CEM. Biologics for psoriasis May, 2005. http://www.accessdermatology.com (accessed 26 March 2009).
95. Hernandez C, Cetner AS, Jordan JE, Puangsuvan SN, Robinson JK. Tuberculosis in the age of biologic therapy. J Am Acad Dermatol 2008; 59(3): 363-380.